I'll be very brief.
Coming out of NAFTA, there was an agreement to work together and share regulatory resources among Canada, Mexico, and the U.S. in order to develop a common approach to setting MRLs. That was so successful that it expanded in a way into what we now call OECD country joint global reviews. The joint global reviews are the model for the future in which PMRA from Health Canada would collaborate with its counterparts in other OECD countries and, as I've mentioned, increasingly with South American countries, such as Brazil, to come up with a common approach.
I think that is the international reference point that represents the solution we would like other countries to increasingly participate in or accept the outcome from, especially as Codex brings us longer and longer delays that increase the trade at risk here.